Stockscreener 앱 받기
3.42
2.01%
-0.07
전일 마감가:
$3.49
열려 있는:
$3.71
하루 거래량:
8,119
Relative Volume:
0.10
시가총액:
$38.07M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-1.9213
EPS:
-1.78
순현금흐름:
$-17.24M
1주 성능:
+12.50%
1개월 성능:
-12.98%
6개월 성능:
+0.88%
1년 성능:
-42.90%
1일 변동 폭
$3.2702
$3.71
1주일 범위
$2.9701
$3.92
52주 변동 폭
$2.55
$7.21
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.42 | 38.07M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges - Investing.com Australia
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
Lantern Pharma : Announces Upcoming Conference Presentations - MarketScreener
Lantern Pharma (NASDAQ:LTRN) Research Coverage Started at Lake Street Capital - The AM Reporter
Lake Street Capital Begins Coverage on Lantern Pharma (NASDAQ:LTRN) - Defense World
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - Nasdaq
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navi - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks
Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - 01net
LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa
Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus
Lantern Pharma Inc Qtrly EPS $-0.54 - MarketScreener
Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks
Preview: Lantern Pharma's Earnings - Benzinga
Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace
Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - Stock Titan
LTRN: M&A Illuminates GBM Value - Yahoo Finance
Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey
Lantern Pharma advances AI-driven drug development with patent - Investing.com India
Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance
Top 10 AI Stocks Dominating Wall Street - Insider Monkey
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey
Lantern Pharma Extends CSO’s Employment Agreement - TipRanks
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lantern Pharma Inc 주식 (LTRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
2.51%
자본화:
|
볼륨(24시간):